Premium
THE TREATMENT OF DISSEMINATED PROSTATE CANCER WITH ESTRAMUSTINE
Author(s) -
Rosenthal M. A.,
Raghavan D.,
StuartHarris R.,
Ackland S.,
Grygiel J.
Publication year - 1992
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1992.tb06942.x
Subject(s) - medicine , estramustine , prostate cancer , cancer , prostate , disease , oncology , urology , urinary system , hormone therapy , prostate disease , breast cancer
Forty‐three patients with disseminated prostate cancer, resistant to orchidectomy or hormone therapy with estramustine were treated. Of the 33 evaluable patients, three patients had stable disease and two had a partial tumour response according to National Prostatic Cancer Project criteria. Twenty‐five patients (58%) showed improvement in pain and urinary symptoms. Ten patients (23%) had side effects requiring cessation of therapy. These results show that estramustine has a limited role in the treatment of advanced prostate cancer and that therapy is frequently associated with intolerable side effects.